Eidos Therapeutics is a clinical stage biopharmaceutical company dedicated to tackling the urgent needs of individuals afflicted by transthyretin amyloidosis, a disease with limited treatment options that can have severe impacts on the heart and nervous system. With a focus on rigorous scientific research, Eidos Therapeutics is committed to discovering and developing innovative therapeutics to improve the lives of patients suffering from this rare, often underdiagnosed, and life-threatening condition. As a leader in the field, Eidos Therapeutics is actively engaged in clinical trials and is proud to announce the exciting Phase 3 trial data in transthyretin amyloidosis cardiomyopathy (ATTR-CM).

This milestone would not have been possible without the invaluable support and participation of patients, their families, physicians, and advocates. Eidos Therapeutics, in partnership with BridgeBio, also emphasizes its commitment to advocating for justice, freedom, and peace for Black Americans. In the words of Dr.

Martin Luther King, Jr., they believe that injustice anywhere threatens justice everywhere. To learn more about Eidos Therapeutics and their groundbreaking work, visit their website